A Premium Hike Is a Relapse Trigger, Not a Billing Problem

She has done everything asked of her. Years abstinent. Appointments kept. Urine screens consistently appropriate. She works. She parents. She plans for the future. Then her marketplace insurance premium went from $40 a month to $138 — nearly $100 more, due every month, to keep the coverage that pays for her buprenorphine, the medication that has kept her stable and off opioids.

That’s the patient Yale addiction medicine fellow John Fomeche describes in STAT News. He doesn’t frame her situation as a budgeting problem.

An insurance bill is not paperwork. For someone taking medication for opioid use disorder, it is a clinical event with the same stakes as a missed dose.

Fomeche’s argument is blunt: “Insurance stability is not ancillary to treatment. It is treatment.” A premium a patient can’t afford, a prior authorization — the extra approval step an insurer requires before it will pay for a refill — that gets delayed, a copay that lands the same week as rent: any of these can interrupt medication continuity, meaning the steady, uninterrupted supply of buprenorphine that keeps withdrawal and cravings from returning. Fomeche calls that interruption a “quiet relapse engine,” and he’s explicit about the mechanism: “Every barrier to treatment increases overdose risk.” Not eventually. Directly.

That’s not just a clinician’s hunch. A 2026 study out of Yale, led by Kaustubh Kulkarni and published in Nature Mental Health, found that craving doesn’t just sit alongside decision-making — it actively rewires it, changing how people weigh rewards and risks moment to moment. Translated: the fear and scarcity of an unaffordable bill isn’t a background stressor your brain shrugs off while you keep making the same sound choices. It can measurably shift how you decide, in real time, the same way craving does. A $98 hike isn’t only a math problem. It’s a psychological event that lands on the same neural circuitry addiction already exploits.

If you’ve ever felt your stomach drop opening a bill you can’t cover, you already know this isn’t abstract. Fomeche’s patient isn’t facing a craving in the clinical sense — she’s facing a threat to “medication continuity. To housing stability. To everything recovery depends on,” as he puts it. For her, and for the patients Fomeche sees across Medicaid, employer, and marketplace plans, the danger isn’t a moment of weakness. It’s a bureaucratic gap nobody built with her recovery in mind.

Fomeche warns that “many more patients will soon face similar disruptions” across marketplace, Medicaid, and employer plans. He’s not describing an edge case. He’s describing the system working as designed, and a patient absorbing the cost of that design in the currency recovery runs on: consistency.

The relapse she’s most at risk for right now won’t start with a craving. It will start with an envelope.